Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Pires

Pain Medicine Santa Barbara, CA Doctor of Osteopathy

NPI 1821135799 CMS profile 899006

3045 De La Vina St, Ste B, Santa Barbara, CA 93105

Open in the dashboard

General payments

$17,836

464 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Pires of Santa Barbara, CA is reported in the CMS Open Payments database as having received $17,836 across 464 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,185 43
2024 General $2,212 57
2023 General $2,796 59
2022 General $2,422 56
2021 General $2,324 84
2020 General $4,109 89
2019 General $2,789 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Pires
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to David Pires were reported at $1,185. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year David Pires Pain Medicine median Middle half National median
2019 $2,789 $498 $126–$1,682 $163
2020 $4,109 $284 $80–$910 $114
2021 $2,324 $399 $112–$1,219 $132
2022 $2,422 $455 $137–$1,484 $149
2023 $2,796 $484 $128–$1,495 $160
2024 $2,212 $498 $131–$1,540 $164
2025 $1,185 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $7,934 238 payments
  2. Nevro Corp. $3,820 72 payments
  3. Boston Scientific Corporation $1,022 45 payments
  4. Medtronic USA, Inc. $850 26 payments
  5. RTI Surgical, Inc. $695 4 payments
  6. Foundation Fusion Solutions, LLC $610 10 payments
  7. Vertiflex, Inc. $593 14 payments
  8. Nalu Medical, Inc. $535 13 payments
  9. Bioventus LLC $347 6 payments
  10. Medtronic, Inc. $344 6 payments
  11. Other $1,086 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,918 461 payments
  2. Consulting Fee $1,400 1 payment
  3. Travel and Lodging $518 2 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $2,917 57 payments
  2. Senza $1,719 30 payments
  3. Senza Spinal Cord Stimulation System $1,644 32 payments
  4. Proclaim IPG $1,510 60 payments
  5. PROCLAIM Neuromodulation $886 24 payments
  6. PROCLAIM Neuromodulation $700 21 payments
  7. COFLEX INTERLAMINAR TECHNOLOGY, 10MM $695 4 payments
  8. Superion ISS $593 14 payments
  9. Nalu Neurostimulation System $535 13 payments
  10. Omnia $426 9 payments
  11. Other $5,746 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Interventional Pain Management: 1,220

Drug cost

$120

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tizanidine Hcl Generic 14 $120

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$111,597

Of which drugs: $1,089

Medicare patients

521

Average age 74

Services billed

2,105

297 women, 224 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Depression 26%
Ischemic heart disease 22%
Chronic kidney disease 21%
Osteoporosis 20%
Diabetes 19%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $10
$10 — —
BOTOX
  • AbbVie, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

464 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record